Randomized, Open-label, Phase 3 Study of Subcutaneous Daratumumab (DARA SC) Versus Active Monitoring in Patients With High-risk Smoldering Multiple Myeloma (SMM): AQUILA

Abstract

Abstract is not available.

    Similar works